About Transcriptional adapter 2-beta
Transcriptional adapter 2-beta (TADA2B) is a protein
from Homo sapiens identified by UniProt accession
Q86TJ2, 420 residues long.
MolForge cross-references it against 0 known binders and
38 disease associations.
Target properties
| Protein name | Transcriptional adapter 2-beta |
|---|
| UniProt accession | Q86TJ2 |
|---|
| Gene | TADA2B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 420 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (38)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.26
- ovarian cancer · score 0.23
- monocyte count · score 0.22
- platelet count · score 0.20
- platelet crit · score 0.20
- neutrophil count · score 0.16
- granulocyte count · score 0.16
- breast carcinoma · score 0.15
- gastric carcinoma · score 0.15
- lymphocyte percentage of leukocytes · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q86TJ2-F1 | alphafold | PREDICTED | 86.67 | — |
Amino-acid sequence (420 residues)
MAELGKKYCV YCLAEVSPLR FRCTECQDIE LCPECFSAGA EIGHHRRYHG YQLVDGGRFT LWGPEAEGGW TSREEQLLLD AIEQFGFGNW EDMAAHVGAS RTPQEVMEHY VSMYIHGNLG KACIPDTIPN RVTDHTCPSG GPLSPSLTTP LPPLDISVAE QQQLGYMPLR DDYEIEYDQD AETLISGLSV NYDDDDVEIE LKRAHVDMYV RKLKERQRRK NIARDYNLVP AFLGKDKKEK EKALKRKITK EEKELRLKLR PLYQFMSCKE FDDLFENMHK EKMLRAKIRE LQRYRRNGIT KMEESAEYEA ARHKREKRKE NKNLAGSKRG KEDGKDSEFA AIENLPGFEL LSDREKVLCS SLNLSPARYV TVKTIIIKDH LQKRQGIPSK SRLPSYLDKV LKKRILNFLT ESGWISRDAS
Explore Transcriptional adapter 2-beta with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets